Merck & Co. (MRK)
(Delayed Data from NYSE)
$97.92 USD
-2.78 (-2.76%)
Updated Jan 17, 2025 04:00 PM ET
After-Market: $97.95 +0.03 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth F Momentum B VGM
Company Summary
Based in Kenilworth, NJ, Merck & Co. boasts more than six blockbuster products in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer and alone accounting for around 50% of its pharmaceutical sales. Keytruda has played an instrumental role in driving Merck’s steady revenue growth in the past few years. Though Keytruda may be Merck’s biggest strength and a solid reason to own the stock, it can also be argued that Merck is excessively dependent on the drug and should look for ways to diversify its product lineup.
<...
Company Summary
Based in Kenilworth, NJ, Merck & Co. boasts more than six blockbuster products in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer and alone accounting for around 50% of its pharmaceutical sales. Keytruda has played an instrumental role in driving Merck’s steady revenue growth in the past few years. Though Keytruda may be Merck’s biggest strength and a solid reason to own the stock, it can also be argued that Merck is excessively dependent on the drug and should look for ways to diversify its product lineup.
Well-known products in Merck’s portfolio include Keytruda (Oncology), Simponi (Immunology), Januvia and Janumet (Diabetes), Bridion and Prevymis (Hospital Acute Care), Isentress (Virology), ProQuad, Gardasil, Pneumovax 23, RotaTeq (Vaccines) and Belsomra (Neuroscience).
In 2009, Merck made its biggest acquisition of Schering-Plough for $41.1 billion. Merck sold off its Consumer Care business to Bayer for $14.2 billion in October 2014. Other key acquisitions include Idenix Pharmaceuticals in August 2014, Cubist Pharmaceuticals in January 2015, Rigontec in October 2017, ArQule in January 2020, Acceleron Pharma in November 2021 and Prometheus Biosciences in 2023.
In June 2021, Merck spun off products from its Women’s Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Merck reported sales of $60.1 billion for 2023, up 1% year over year. While the Pharmaceuticals segment accounted for 89.1% of total sales, Animal Health products generated 10.9% of total revenues. Key drug, Keytruda recorded sales of $25.0 billion in 2023, up 19% year over year.
General Information
Merck & Co, Inc
126 East Lincoln Avenue
Rahway, NJ 07065
Phone: 908-740-4000
Fax: 908-735-1253
Web: http://www.merck.com
Email: investor_relations@merck.com
| Industry | Large Cap Pharmaceuticals |
| Sector | Medical |
| Fiscal Year End | December |
| Last Reported Quarter | 12/31/2024 |
| Earnings Date | 2/4/2025 |
EPS Information
| Current Quarter EPS Consensus Estimate | 1.76 |
| Current Year EPS Consensus Estimate | 7.70 |
| Estimated Long-Term EPS Growth Rate | 9.00 |
| Earnings Date | 2/4/2025 |
Price and Volume Information
| Zacks Rank |  |
| Yesterday's Close | 100.70 |
| 52 Week High | 134.63 |
| 52 Week Low | 94.48 |
| Beta | 0.39 |
| 20 Day Moving Average | 7,098,219.00 |
| Target Price Consensus | 129.22 |
| 4 Week | -0.13 |
| 12 Week | -5.83 |
| YTD | -1.57 |
| 4 Week | -1.23 |
| 12 Week | -8.79 |
| YTD | -3.46 |
| Shares Outstanding (millions) | 2,529.64 |
| Market Capitalization (millions) | 247,701.91 |
| Short Ratio | NA |
| Last Split Date | 2/17/1999 |
| Dividend Yield | 3.31% |
| Annual Dividend | $3.24 |
| Payout Ratio | 0.52 |
| Change in Payout Ratio | -0.10 |
| Last Dividend Payout / Amount | 12/16/2024 / $0.81 |
Fundamental Ratios
| P/E (F1) | 10.37 |
| Trailing 12 Months | 16.46 |
| PEG Ratio | 1.15 |
| vs. Previous Year (Q0/Q-4) | -26.29% |
| vs. Previous Quarter (Q0/Q-1) | -31.14% |
| vs. Previous Year (Q0/Q-4) | 4.35% |
| vs. Previous Quarter (Q0/Q-1) | 3.38% |
| Price/Book | 5.57 |
| Price/Cash Flow | 32.19 |
| Price / Sales | 3.92 |
| 12/31/24 | Pending Next EPS Report |
| 9/30/24 | 36.42 |
| 6/30/24 | 40.69 |
| 12/31/24 | Pending Next EPS Report |
| 9/30/24 | 13.68 |
| 6/30/24 | 15.36 |
| 12/31/24 | Pending Next EPS Report |
| 9/30/24 | 1.36 |
| 6/30/24 | 1.47 |
| 12/31/24 | Pending Next EPS Report |
| 9/30/24 | 1.15 |
| 6/30/24 | 1.22 |
| 12/31/24 | Pending Next EPS Report |
| 9/30/24 | 23.96 |
| 6/30/24 | 26.54 |
| 12/31/24 | Pending Next EPS Report |
| 9/30/24 | 19.23 |
| 6/30/24 | 21.99 |
| 12/31/24 | Pending Next EPS Report |
| 9/30/24 | 21.72 |
| 6/30/24 | 24.41 |
| 12/31/24 | Pending Next EPS Report |
| 9/30/24 | 17.59 |
| 6/30/24 | 17.23 |
| 12/31/24 | Pending Next EPS Report |
| 9/30/24 | 2.39 |
| 6/30/24 | 2.43 |
| 12/31/24 | Pending Next EPS Report |
| 9/30/24 | 0.79 |
| 6/30/24 | 0.80 |
| 12/31/24 | Pending Next EPS Report |
| 9/30/24 | 43.98 |
| 6/30/24 | 44.30 |